Amedisys (AMED) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
2.3B
Gross Profit
1.0B
43.34%
Operating Income
209.6M
8.92%
Net Income
38.2M
1.63%
EPS (Diluted)
$1.31
Balance Sheet Metrics
Total Assets
2.1B
Total Liabilities
958.7M
Shareholders Equity
1.2B
Debt to Equity
0.81
Cash Flow Metrics
Operating Cash Flow
144.5M
Free Cash Flow
214.3M
Revenue & Profitability Trend
Amedisys Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.3B | 2.2B | 2.2B | 2.2B | 2.1B |
| Cost of Goods Sold | 1.3B | 1.2B | 1.3B | 1.2B | 1.2B |
| Gross Profit | 1.0B | 990.9M | 962.8M | 980.8M | 886.2M |
| Operating Expenses | 790.1M | 780.1M | 754.1M | 697.9M | 633.9M |
| Operating Income | 209.6M | 193.1M | 183.8M | 251.9M | 223.4M |
| Pre-tax Income | 86.2M | 39.6M | 160.2M | 280.2M | 210.8M |
| Income Tax | 48.1M | 50.6M | 42.5M | 70.1M | 25.6M |
| Net Income | 38.2M | -10.9M | 117.7M | 210.2M | 185.2M |
| EPS (Diluted) | $1.31 | -$0.30 | $3.63 | $6.34 | $5.52 |
Income Statement Trend
Amedisys Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 632.1M | 496.9M | 389.0M | 356.7M | 362.0M |
| Non-Current Assets | 1.5B | 1.6B | 1.6B | 1.5B | 1.2B |
| Total Assets | 2.1B | 2.1B | 2.0B | 1.9B | 1.6B |
| Liabilities | |||||
| Current Liabilities | 514.4M | 473.7M | 355.5M | 374.3M | 456.3M |
| Non-Current Liabilities | 444.4M | 466.7M | 514.1M | 506.4M | 300.1M |
| Total Liabilities | 958.7M | 940.4M | 869.7M | 880.6M | 756.5M |
| Equity | |||||
| Total Shareholders Equity | 1.2B | 1.1B | 1.1B | 976.3M | 810.7M |
Balance Sheet Composition
Amedisys Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 38.2M | -10.9M | 117.7M | 210.2M | 185.2M |
| Operating Cash Flow | 144.5M | 116.7M | 163.9M | 246.6M | 264.8M |
| Investing Activities | |||||
| Capital Expenditures | -6.6M | -5.5M | -6.1M | -6.2M | -5.3M |
| Investing Cash Flow | -7.5M | 42.2M | -93.4M | -281.2M | -287.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -49.2M | -90.2M | -36.6M | -1.9M | -43.9M |
| Free Cash Flow | 214.3M | 124.5M | 126.1M | 182.2M | 283.6M |
Cash Flow Trend
Amedisys Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
35.87
Forward P/E
19.02
Price to Book
2.66
Price to Sales
1.35
PEG Ratio
19.02
Profitability Ratios
Profit Margin
3.79%
Operating Margin
10.11%
Return on Equity
7.15%
Return on Assets
6.36%
Financial Health
Current Ratio
1.29
Debt to Equity
36.30
Beta
0.94
Per Share Data
EPS (TTM)
$2.71
Book Value per Share
$36.55
Revenue per Share
$72.42
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| amed | 3.2B | 35.87 | 2.66 | 7.15% | 3.79% | 36.30 |
| HCA Healthcare | 91.0B | 16.80 | -209.92 | 1,605.77% | 8.07% | -106.02 |
| Tenet Healthcare | 15.7B | 10.85 | 3.76 | 28.82% | 7.09% | 152.20 |
| Ensign Group | 8.5B | 27.83 | 4.37 | 17.64% | 7.00% | 104.09 |
| Chemed | 6.8B | 22.67 | 5.73 | 26.11% | 12.40% | 12.28 |
| Option Care Health | 5.1B | 24.78 | 3.76 | 15.38% | 4.12% | 90.53 |
Financial data is updated regularly. All figures are in the company's reporting currency.